Q-omics provides the consensus-scored REEP5 profile across patient tissues and cancer cell-line models. REEP5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, REEP5 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, REEP5 protein abundance shows 19,526 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, THCA, and LSCC as cancer lineages where REEP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REEP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REEP5 survival associations across molecular data types. REEP5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REEP5 RNA expression–survival associations across cancer types. High REEP5 expression shows unfavorable associations in HNSC, UVM, STAD and SCLC, but favorable associations in KIRC and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for REEP5 RNA expression.
This table summarizes REEP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for REEP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REEP5 shows lower tumor expression in THCA, LUSC, KIRP, LUAD and UCEC and higher tumor expression in CHOL. The THCA box plot shows higher REEP5 RNA expression in normal versus tumor tissue (log2 FC = −0.636, t-test p < 0.001).
This table shows molecular features associated with REEP5 in patient tissues and cancer cell lines. In patient samples, REEP5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, REEP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
